


Product Details

| | | | |
|-----------------|-------------------------------------------------------------------------|--------------------|-----------------|
| Product name: | Anti-human ERBB2 / HER2 / CD340 (trastuzumab Biosimilar) | SKU: | BIO0037SM |
| Target Name: | ERBB2 / HER2 / CD340 | Size: | 1 mg/5 mg/20 mg |
| Target Uniprot: | P04626 | Concentration: | Lyophilized |
| Clone#: | trastuzumab | Isotype: | Human IgG1 |
| Reactivity: | Human, Mouse | Calculated M.W.: | 145.36 kDa |
| Application: | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | Endotoxin: | <0.001 EU/ug |
| Formulation: | 0.1M Pro, 20mM Arg, pH5.0 | Conjugation: | None |
| Storage: | For long term storage, the produce should be stored at -20° C or lower. | Expression System: | CHO |
| Reconstitution: | Dissolve with sterile ddH2O | Purification: | Protein A |


Data

Purity:SDS-PAGE




Anti-ERBB2 / HER2 / CD340 (trastuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC




The purity of Anti-ERBB2 / HER2 / CD340 (trastuzumab) is more than 95%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human HER2, His at 2 ug/mL can bind Anti-ERBB2 / HER2 / CD340 (trastuzumab), EC₅₀=0.005735 ug/mL.


Bioactivity:FACS



BT474 cells were stained with Anti-ERBB2 / HER2 / CD340 (trastuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC₅₀=0.3024 ug/mL.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Research in vivo



Trastuzumab inhibited the tumor growth of BT474 on NCG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 88.5% at 10 mpk at D35.